About MacroGenics
MacroGenics is a company based in Rockville (United States) founded in 2000. It operates as a Professional Services. MacroGenics has raised $126.02 million across 13 funding rounds from investors including Lilly, ARE and NIH. The company has 341 employees as of December 31, 2024. MacroGenics has completed 1 acquisition, including Raven Biotechnologies. MacroGenics offers products and services including Lorigerlimab, MGC026, MGC028, and MGD024. MacroGenics operates in a competitive market with competitors including argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others.
- Headquarter Rockville, United States
- Employees 341 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Macrogenics, Inc.
-
Annual Revenue
$149.96 M155.26as on Dec 31, 2024
-
Net Profit
$-66.97 M-639.3as on Dec 31, 2024
-
EBITDA
$-103.04 M35.03as on Dec 31, 2024
-
Total Equity Funding
$126.02 M (USD)
in 13 rounds
-
Latest Funding Round
-
Investors
Lilly
& 22 more
-
Employee Count
341
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MacroGenics
MacroGenics is a publicly listed company on the NASDAQ with ticker symbol MGNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MacroGenics
MacroGenics offers a comprehensive portfolio of products and services, including Lorigerlimab, MGC026, MGC028, and MGD024. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative antibody therapy targeting PD-1 and CTLA-4 proteins.
Antibody-drug conjugate targeting B7-H3 for cancer treatment.
Antibody-drug conjugate targeting ADAM9 for cancer therapy.
Bispecific antibody targeting CD123 and CD3 molecules.
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Software Development Team
17 people
Operations Team
12 people
Data Analysis and Operations Team
11 people
Product Management Team
8 people
Senior Team
4 people
Finance and Accounting
3 people
Associate Team
3 people
Unlock access to complete
Funding Insights of MacroGenics
MacroGenics has successfully raised a total of $126.02M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Last Round
-
First Round
First Round
(25 Sep 2001)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2019 | Amount | Post-IPO - MacroGenics | Valuation |
investors |
|
| Jan, 2011 | Amount | Series D - MacroGenics | Valuation |
investors |
|
| Jul, 2010 | Amount | Grant - MacroGenics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MacroGenics
MacroGenics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, ARE and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Arcus Ventures is focused on investing in oncology companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MacroGenics
MacroGenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Raven Biotechnologies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibodies targeting cell surfaces for cancer therapies are developed.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MacroGenics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Macrogenics Comparisons
Competitors of MacroGenics
MacroGenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Macrogenics
Frequently Asked Questions about MacroGenics
When was MacroGenics founded?
MacroGenics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Where is MacroGenics located?
MacroGenics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Is MacroGenics a funded company?
MacroGenics is a funded company, having raised a total of $126.02M across 13 funding rounds to date. The company's 1st funding round was a Grant of $9.8M, raised on Sep 25, 2001.
How many employees does MacroGenics have?
As of Dec 31, 2024, the latest employee count at MacroGenics is 341.
What is the annual revenue of MacroGenics?
Annual revenue of MacroGenics is $149.96M as on Dec 31, 2024.
What does MacroGenics do?
MacroGenics, Inc. is engaged in the development and commercialization of innovative monoclonal antibody-based therapeutics for cancer treatment. The company operates within the biopharmaceutical sector, focusing on unmet medical needs through a broad pipeline of investigational product candidates. Solutions are developed using advanced antibody-based technologies and fully-integrated development capabilities, including GMP manufacturing. Efforts are directed towards creating breakthrough biologics aimed at transforming patient outcomes in oncology.
Who are the top competitors of MacroGenics?
MacroGenics's top competitors include argenx, Zai Lab and Kodiak Sciences.
What products or services does MacroGenics offer?
MacroGenics offers Lorigerlimab, MGC026, MGC028, and MGD024.
Is MacroGenics publicly traded?
Yes, MacroGenics is publicly traded on NASDAQ under the ticker symbol MGNX.
How many acquisitions has MacroGenics made?
MacroGenics has made 1 acquisition, including Raven Biotechnologies.
Who are MacroGenics's investors?
What is MacroGenics's ticker symbol?
The ticker symbol of MacroGenics is MGNX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.